SCHEMBL190640

SCHEMBL190640

COc1ccc(N2C(=O)NC(=O)C23CCCCC3)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.55
MAPK1 P28482 1/20 0.55
SMN1; SMN2 Q16637 6/20 0.51
RAB9A P51151 5/20 0.51
KDM4E B2RXH2 4/20 0.51
NPC1 O15118 4/20 0.51
HPGD P15428 2/20 0.51
TP53 P04637 1/20 0.51
TSHR P16473 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPT P10636 2/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201840 0.83 POLB (0.51) ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1
SCHEMBL421867 0.80 AKR1B1 (0.37) ALDH1A1MAPK1SMN1; SMN2RAB9AKDM4E
SCHEMBL17077228 0.80 MAPT (0.45) ALDH1A1NPC1MAPT
SCHEMBL721033 0.79 CHRNB2 (0.44) ALDH1A1MAPK1SMN1; SMN2NPC1MEN1
SCHEMBL18961831 0.79 LMNA (0.46) SMN1; SMN2HSD17B10MAPTGRIN1GRIN2A
SCHEMBL2544529 0.77 MMP13 (0.46) SMN1; SMN2HSD17B10MAPTGRIN1GRIN2A
SCHEMBL18961737 0.77 ALDH1A1 (0.52) ALDH1A1MAPK1SMN1; SMN2RAB9AKDM4E
SCHEMBL20340391 0.77 SLC6A9 (0.59) ALDH1A1MAPK1HSD17B10
SCHEMBL20340469 0.75 CYP17A1 (0.37) ALDH1A1MAPK1POLB
SCHEMBL20340428 0.74 ALDH1A1 (0.44) ALDH1A1MAPK1SMN1; SMN2RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10011601-B2 Substituted spirocyclic inhibitors of autotaxin X-RX, INC. (US) 2018-07-03 US disclosed
US-20170166568-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. (US) 2017-06-15 US disclosed
US-20120045500-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-23 US disclosed
EP-2401262-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM Galderma Research & Development (FR) 2012-01-04 EP disclosed
WO-2010097469-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166568-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN ENPP2, SLC10A1, CXCR3 ALDH1A1 1493/4885MAPK1 679/4885SMN1; SMN2 2129/4885
US-20120045500-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM SOAT1, SOAT2, ODC1 ALDH1A1 19/4885MAPK1 1264/4885SMN1; SMN2 4383/4885
US-10011601-B2 Substituted spirocyclic inhibitors of autotaxin ENPP2, SLC10A1, CXCR3 ALDH1A1 1493/4885MAPK1 679/4885SMN1; SMN2 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.